Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.44 - A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine
D1.45 - Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report
D1.48 - Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation
D1.49 - Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions
D1.50 - Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy
D1.53 - Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis
D1.54 - Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests
D1.55 - Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis’s box?
D1.46 - Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists
D3.420 - IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas
D3.422 - Evaluating Elevated Baseline Mast Cell Tryptase: Insights from an Adult Allergy Service
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download